Registry of Chinese patients with AL amyloidosis treated with daratumumab
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
This study is tracking how well daratumumab works for Chinese patients with AL amyloidosis when used alone or with chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | daratumumab, chemotherapy |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05277493 on ClinicalTrials.gov |
What this trial studies
This registry aims to collect data on Chinese patients diagnosed with AL amyloidosis who are treated with either subcutaneous or intravenous daratumumab, alone or in combination with chemotherapy. The observational study will track treatment outcomes and patient responses to better understand the efficacy of daratumumab in this specific population. By compiling this information, the registry seeks to enhance knowledge about treatment patterns and outcomes in AL amyloidosis.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have newly diagnosed or refractory/relapsed AL amyloidosis and are receiving daratumumab treatment.
Not a fit: Patients with co-diagnoses of multiple myeloma or Waldenström's macroglobulinemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights that improve treatment strategies for patients with AL amyloidosis.
How similar studies have performed: While this registry approach is common, the specific focus on daratumumab in AL amyloidosis within the Chinese population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years and older * newly diagnosed or refractory/relapsed AL amyloidosis * treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy Exclusion Criteria: * co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia
Where this trial is running
Beijing
- Peking Union Medical College Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Daobin Zhou, MD
- Email: zhoudb@pumch.cn
- Phone: 69155020
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.